SNSita Naik

Sita Naik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sita Naik has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Rakesh Aggarwal

    Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    9 shared publications
  • Amita Aggarwal

    Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India

    5 shared publications
  • Subhash R Naik

    Departments of *Immunology and †Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences and Departments of ‡Obstetrics and Gynecology and §Medicine, King George's Medical University, Lucknow, India

    4 shared publications
  • Amita Aggarwal

    Department of Immunology, Sanjay Gandhi Post‐Graduate Institute of Medical Sciences, Lucknow 226 014, India

    3 shared publications
  • Ramnath Misra

    Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    3 shared publications
  • Rekha Pal

    Department of Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    3 shared publications

Latest Publications

  • Open Access

    O2 Anti-chromatin antibodies in SLE: which is the best antibody to use in clinical practice?

    by Awadesh Pratap Singh, Vineeta Khare, Sita Naik, Ramnath Misra, Amita Aggarwal

  • Open Access

    Cytokines and Inflammatory Mediators [30-39]: 30. The LPS Stimulated Production of Interleukin-10 is not Associated with -819C/T and -592C/A Promoter Polymorphisms in Healthy Indian Subjects

    by Skanda Shukla, Able Lawrence, Amita Aggarwal, Sita Naik, N. J. Gullick, H. G. Evans, D. Jayaraj, B. W. Kirkham, L. S. Taams, S. M. Judah, et al.

    Background: Interleukin-10 is a pivotal immunoregulatory cytokine with pleiotropic effects on the immune system. IL-10 promoter polymorphisms have been associated with disease susceptibility and the ability to secrete IL-10 in vitro. We suspected that the association of the widely studied -819C/T and -592C/A polymorphisms with the IL-10 production might vary between ethnic groups. Therefore, we examined the association of -819 C/T and -592 C/A promoter polymorphisms with in vitro LPS stimulated secretion of IL-10 in normal healthy Indian volunteers. Methods: Peripheral blood was collected from 103 healthy volunteers and diluted whole blood cultures were set up with 100 ng/ml of LPS as stimulant: supernatant was collected at 24 h and IL-10 levels were assayed by ELISA. Genotyping was done for -819C/T polymorphism in 101 individuals and -592C/A polymorphism in 68 individuals by polymerase chain reaction followed by RFLP. The differences in IL-10 production between the genotypes were analysed by ANOVA. Results: There were 30, 47 and 24 individuals with the CC, CT and TT genotypes with a minor allele (T) frequency of 47% for the -819C/T polymorphism. The CC and TT genotypes at position -819 were strongly associated with CC and AA genotypes at -592 position suggestive of strong linkage disequilibrium. There was no association between the -819 genotype and the in vitro LPS stimulated IL-10 levels. Conclusions: The -819C/T and the -592 C/A polymorphisms of the IL-10 promoter region are not significantly associated with LPS stimulated IL-10 production healthy Indian subjects. Disclosure statement: All authors have declared no conflicts of interest.

  • Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E

    by R. Srivastava, R. Aggarwal, M. R. Bhagat, A. Chowdhury, S. Naik

    Summary.  The mechanism of liver damage in acute hepatitis E is poorly understood. In this study, we assessed the frequency and activation status of natural killer (NK) and natural killer T (NKT) cells and cytotoxic activity of NK cells in the peripheral blood mononuclear cells (PBMCs) obtained from patients with hepatitis E (n = 41) and healthy controls (n = 61). Flow cytometry was used to assess NK (CD3−/CD56+) and NKT cell (CD3+/CD56+) fractions (% of PBMCs) and activation status (CD69+; % of NK, NKT cells). NK cell cytotoxicity was assessed using major histocompatibilities complex‐deficient K562 cells as target cells. In 14 patients, the studies were repeated during the convalescence period. Patients had fewer median (range) NK cells [8.9% (2.4–47.0) vs 11.2% (2.6–35.4)] and NKT cells [8.7% (2.8–34.1) vs 13.6% (2.3–36.9)] than controls (P < 0.05 each). Activation markers were present on large proportion of NK cells [43.5% (11.2–58.6) vs 15.5% (3.0–55.8)] and NKT cells [41.5% (17.4–71.1) vs 12.8% (3.3–63.2); P < 0.05 each] from patients. NK cell cytotoxicity was similar in patients and controls. During convalescence, all the parameters normalized. In conclusion, reversible alterations in NK and NKT cell number and activation status during acute hepatitis E suggest a role of these cells in the pathogenesis of this disease.


  • Open Access

    Prophylactic Efficacy of High‐Molecular‐Weight Antigenic Fractions of a Recent Clinical Isolate of Leishmania donovani Against Visceral Leishmaniasis

    by P. Tripathi, S. K. Gupta, S. Sinha, S. Sundar, A. Dube, S. Naik

    T‐cell mediated immune responses are key determinants to the natural course of infection caused by intracellular parasites such as Leishmania. Thus, T‐cell activating proteins of these microbes continue to generate active interest particularly in view of their possible role in the design and development of newer and more effective vaccines. We have recently reported the presence of T‐cell immunostimulatory antigens with the high‐molecular‐weight (MW) fractions (134–64.2 kDa) of whole Leishmania donovani antigen (strain 2001), which stimulated variable amounts of IFN‐γ, IL‐12 and IL‐10 in exposed immune individuals. The present study was undertaken to further evaluate these high‐MW antigenic fractions (MW range >100–60 kDa) for potential protective efficacy. The high‐MW region of the parasite was resolved into five antigenic fractions (Prep A–E) using continuous elution gel electrophoresis. Prior to in vivo protection studies in hamsters, these fractions were used to evaluate in vitro cellular responses in eight Leishmania‐exposed individuals and treated cured hamsters. The protective efficacy of prep (A + B), C, D and E in combination with BCG was evaluated in inbred hamsters using standard immunization protocol. Proliferative responses were seen in all eight of eight exposed individuals to prep D [median stimulation index (SI): 5.2 (range 3.9–7.1)] and E [median SI: 5.6 (range 4.4–8.2)], five of eight individuals to prep B and prep C and three of eight to prep A [median SI: 0.2 (range 0.1–7.2)]. The median proliferative responses to prep D and prep E were significantly higher than to fraction prep A; (P < 0.05) but not to prep B and prep C. However, prep A–E induced equivalent levels of IFN‐γ, IL‐10 and IL‐12 cytokines. Fractions D and E also exhibited marked parasite inhibition in spleen (52.5% and 73.7%) and liver (65% and 80.2%) as compared with prep (A + B) (23% in spleen and 24% in liver) and prep C (38% in spleen and 24% in liver). Prep D and prep E vaccinated animals showed higher in vitro stimulatory responses (mean SI: 6.6 and 8.8) and nitric oxide (NO) induction (mean NO levels: 6.4 and 10.7 μg/ml) against whole cell extract as compared with other groups. The protection also correlated with presence of suppressed Leishmania‐specific IgG levels in prep D and prep E immunized hamsters. These studies indicate the presence of immunostimulatory and protective molecules in 60–80 kDa region of L. donovani, which may be further exploited for developing a subunit vaccine.


  • Open Access

    Leishmania donovaniinfection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism

    by Dinesh Chandra, Sita Naik

    The failure of Leishmania, an intracellular pathogen, to stimulate a pro-inflammatory response following entry into macrophages has been well reported. This occurs in spite of the fact that ligands for the toll-like receptors (TLR) have been recently shown on the parasite surface and their role in disease protection well documented. The outcome of infection in leishmaniasis is determined by the Th1 versus Th2 nature of the effector response and the generation of IL-12 and IL-10 by the infected macrophages is important for this decision. We evaluated the effect of L. donovani infection of monocytes (cell line THP-1, and monocytes derived from human peripheral blood) on Pam3cys (TLR2 ligand) and lipopolysaccharide (TLR4 ligand) stimulated production of IL-12p40 and IL-10. L. donovani infection caused suppression of TLR2 and TLR4-stimulated IL-12p40, with an increase in IL-10 production. Parasites also modulated the TLR2-stimulated mitogen-activated protein kinase (MAPK) pathway by suppressing MAPK P38 phosphorylation and activating extracellular regulated kinase (ERK)1/2 phosphorylation. These effects could be reversed either by using a MAPK P38 activator, anisomycin, or ERK1/2 inhibitor, U0126. L. donovani caused modulation of TLR2-stimulated MAPK pathways in a contact-dependent mechanism. In addition parasite structural integrity but not viability was required for suppression of TLR2-stimulated IL-12p40 and activation of IL-10. These observations suggest that L. donovani has evolved survival strategies that subvert the pro-inflammatory response generated through TLRs.


  • Withania somnifera inhibits NF‐κB and AP‐1 transcription factors in human peripheral blood and synovial fluid mononuclear cells

    by Divya Singh, Amita Aggarwal, Rakesh Maurya, Sita Naik

    Withania somnifera (WS) is an important herb with known antiinflammatory activity. Its molecular mechanism of action has not been investigated. The effect of a WS crude ethanol extract was studied on peripheral blood mononuclear cells of normal individuals and rheumatoid arthritis (RA) patients and synovial fluid mononuclear cells of RA patients in vitro. The WS extract significantly suppressed lipopolysaccharide (LPS) induced production of proinflammatory cytokines TNF‐α, IL‐1β and IL‐12p40 in normal individuals and RA patients, but had no effect on IL‐6 production at the protein and transcript level. WS also suppressed LPS activated nitric oxide production in the mouse macrophage cell line, RAW 264.7. The extract inhibited nuclear translocation of the transcription factors NF‐κB and AP‐1 and phosphorylation of IκBα in normal and RA patients' mononuclear cells. HPLC analysis of the crude extract showed the presence of withaferin A and pure withaferin A also inhibited NF‐κB translocation.The study demonstrated that the WS crude ethanol extract suppressed the production of proinflammatory molecules in vitro. This activity is partly through the inhibition of transcription factors NF‐κB and AP‐1 by the constituent withanolide. The role of additional constituents needs to be studied. Studies on the mechanism of action of the extract may yield potentially useful compounds for the treatment of inflammatory diseases. Copyright © 2007 John Wiley & Sons, Ltd.


    • 1 July 2007
      • Vol. 126  (1) , 34-8

    Antinuclear antibodies by indirect immunofluorescence : optimum screening dilution for diagnosis of systemic lupus erythematosus.

    by P Ghosh, S Dwivedi, Sita Naik, Vikas Agarwal, Anupam Verma, Amita Aggarwal, Ramnath Misra

    Antinuclear antibodies (ANA) are serological hallmark of systemic lupus erythematosus (SLE). Conventionally, the test is carried out on human epithelial cells (HEp2) by indirect immunofluorescence (IIF) technique. Since culturing and maintaining HEp2 cells in the laboratory are labour intensive, in-house assays have given way to kits manufactured by commercial companies. The reference screening dilutions provided by the manufacturers are based on different ethnic population than ours. Therefore, it becomes mandatory for every laboratory to have its own screening dilutions for the local population that distinguishes best between healthy and diseased state. As, there is paucity of such data, we aimed to define the optimum screening dilution that distinguishes the patient with SLE from healthy individuals. Sera of patients fulfilling ACR criteria for diagnosis of SLE, idiopathic inflammatory polymyositis/dermatomyositis (PM/DM) and rheumatoid arthritis (RA), and age and sex matched healthy individuals were tested for ANA by IIF using a commercial kit (Euroimmun, Germany) at 5 dilutions, namely 1:40, 1:80, 1:160, 1:320 and 1:640. Receiver operator characteristics (ROC) curve were constructed to define the optimum dilution that distinguished healthy sera from the diseased ones. Test was performed on 213 sera from 94 healthy individuals, and 43 SLE, 37 RA and 39 DM/PM patients. In healthy individuals, ANA at dilutions 1:40, 1:80, 1:160, 1:320 and 1:640 was positive in 13.8, 4.3, 2.1, 2.1 and 0 per cent respectively, whereas in SLE it was positive in 95.3, 95.3, 65.1, 53.5 and 23.3 per cent respectively. ROC curves analysis showed that at 1:40 dilution, sera of 95.3 per cent of SLE and 13.8 per cent of normal individuals were (ANA) positive, whereas at 1:80 dilution it was 95.3 per cent for SLE and 4.3 per cent for healthy individuals. A fluorescent intensity of > or =2 was more specific for SLE. The best discrimination between healthy individuals and the SLE patients was found at screening dilution of 1:80 and fluorescent intensity of > or =2 in our laboratory.


  • Cellular Immune Responses in Acute Hepatitis E Virus Infection to The Viral Open Reading Frame 2 Protein

    by Ruchi Srivastava, Rakesh Aggarwal, Shahid Jameel, Pankaj Puri, Vijay K. Gupta, V.S. Ramesh, Shobna Bhatia, Sita Naik

    Hepatitis E virus (HEV) causes acute viral hepatitis and is endemic in the developing world. Few data are available on cellular immune responses in HEV infection. Using flow cytometry, we studied the frequencies of peripheral blood CD4+ /CD8+ T cells secreting interferon (IFN)-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-4 in 21 patients with acute hepatitis E and 18 healthy controls, after stimulation with the HEV capsid (ORF2) protein. Cytokine levels in serum specimens and culture supernatants of ORF2-stimulated peripheral blood mononuclear cells (PBMCs) were estimated in enzyme-linked immunosorbent assays. In addition, cytokine mRNA transcripts were measured in PBMCs by reverse transcription-polymerase chain reaction. In patients with acute hepatitis E, although the total CD4+ population was expanded, the proportions of CD4+/CD69+ and CD8+ /CD69+ cells producing IFN-γ, TNF-α, and IL-4 in response to HEV ORF2 stimulation were unchanged. However, IFN-γ levels in the supernatants and IFN-γ mRNA transcripts in cells were elevated in ORF2-stimulated PBMCs in acute hepatitis E; levels of IL-2 or TNF-α were unchanged. Our findings suggest that CD4+ IFN-γ-secreting cells, which do not belong either to the helper T cell type 1 or type 2 phenotype, as is the case with natural killer T cells, may be involved in the pathogenesis of hepatitis E. Further, the limited immune reactivity we detected in peripheral blood cells may be related to the sequestration of immune events to the intrahepatic compartment, which is the major disease site.


    • 1 November 2006
      • Vol. 124  (5) , 521-6

    Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.

    by Parshant Aggarwal, Sita Naik, K P Mishra, Amita Aggarwal, Ramnath Misra

    C677T polymorphism in the methylenetetrahydrofolate reductase (MTHFR) gene has been proposed as a pharmacogenomic marker for toxicity of methotrexate (MTX). We studied the relationship between the C677T gene polymorphism and toxicity and efficacy of MTX in patients with rheumatoid arthritis (RA) on folate supplementation. A total of 150 RA patients fulfilling American College of Rheumatology (ACR) criteria and on MTX treatment were evaluated. The mean age of the patients was 42.9 +/- 11.1 yr, mean disease duration was 7.65 +/- 5.2 yr and the mean duration of MTX treatment was 26.1 +/- 20.6 months. Genotype analysis of MTHFR gene was done by PCR and restriction enzyme method. Primary endpoint for treatment efficacy was change in disease activity score 28 (DAS28) from baseline. Drug toxicity was evaluated by blood count, renal and liver function tests and a standardized questionnaire. The mean DAS at baseline was 5.02 +/- 0.8. All patients received 10 mg/wk folic acid supplementation. Forty two per cent (63/150) of the patients had C677T polymorphism of which 4 were homozygous (T/T) and 59 were heterozygous (C/T). The baseline characteristics of the patients with or without polymorphism were comparable. The frequency of adverse events was not increased in patients with C677T polymorphism with 11 patients experiencing adverse events as compared to 19 in the group without polymorphism (of whom 4 and 7 patients respectively discontinued treatment). The C677T polymorphism was not associated with any difference in response to treatment. Our findings suggest that C677T polymorphism in the MTHFR gene is not predictive of toxicity or efficacy of MTX treatment in RA patients receiving folate supplementation. Further studies need to be done to look at polymorphisms in other enzymes that may have association with MTX clinical efficacy and toxicity.